Mode
Text Size
Log in / Sign up
N/A N=2 Single-blind Treatment

Feasibility Study: Heavy Water Tissue Labeling Protocol

Skin Laxity

Enrolled (actual)
2
Serious AEs
0.0%
Results posted
Dec 2014
Primary outcome: Primary: Rate of Collagen Synthesis — 15.71; 21.22; 36.11; 51.80 percentage of new collagen synthesized

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Ulthera® System Treatment (Device); Heavy Water (Other)
Age
Adult, Older Adult · 30+ yrs
Sex
All
Sponsor
Ulthera, Inc
Primary completion
Nov 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Rate of Collagen Synthesis
15.71; 21.22; 36.11; 51.80; 18.53; 29.69

Summary

Enrolled subjects undergo tissue labeling to evaluate the rate of collagen synthesis in tissue treated with the Ulthera® System compared to control tissue.

Eligibility Criteria

Inclusion Criteria

  • Male or female, age 30 to 65 years scheduled for rhytidectomy.
  • Subject in good health.
  • Understands and accepts the obligation not to undergo any other procedures in the areas to be treated.
  • Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.
  • Subjects of childbearing potential must have a negative urine pregnancy test result and must not be lactating at Visit 1 and be willing and able to use an acceptable method of birth control.
  • Absence of physical or psychological conditions unacceptable to the investigator.
  • Willingness and ability to provide written consent for study-required photography and adherence to photography procedures (i.e., removal of jewelry and makeup).
  • Willingness and ability to provide written informed consent and HIPAA authorization prior to performance of any study-related procedure.

Exclusion Criteria

  • Presence of an active systemic or local skin disease that may affect wound healing.
  • Severe solar elastosis.
  • Significant scarring in areas to be treated.
  • Open wounds or lesions in the area to be treated.
  • Severe or cystic acne on the area to be treated.
  • Presence of a metal stent or implant in the facial area to be treated.
  • Inability to understand the protocol or to give informed consent.
  • Microdermabrasion, or prescription level glycolic acid treatments to the submental area within two weeks prior to study participation or during the study.
  • Excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin in the area to be treated.
  • BMI equal to or greater than 30.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01708525). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search